Celcuity

Celcuity Net Debt

The Net Debt of Celcuity (CELC) as of Oct 8, 2026 is -119.59 M USD. In the previous year, Net Debt was -137.38 M USD — a change of -12.95% (higher).

Net Debt

-119.59 MUSD

YoY

-12.95%

Last updated:

Net Debt of Celcuity is 2025 -119.59 M USD. Net Debt of Celcuity was 2024 -137.38 M USD. It decreases by -12.95% higher compared to the previous year.

The Celcuity Net Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt
Date
Net Debt
Jan 1, 2018
-24.90 M USD
Jan 1, 2019
-18.76 M USD
Jan 1, 2020
-11.66 M USD
Jan 1, 2021
-69.69 M USD
Jan 1, 2022
-133.59 M USD
Jan 1, 2023
-143.55 M USD
Jan 1, 2024
-137.38 M USD
Jan 1, 2025
-119.59 M USD
The Celcuity Net Debt history
YEARNet DebtYoY
-119.59 MUSD-12.95%
-137.38 MUSD-4.30%
-143.55 MUSD+7.46%
-133.59 MUSD+91.70%
-69.69 MUSD+497.66%
-11.66 MUSD-37.84%
-18.76 MUSD-24.66%
-24.90 MUSD+2.90%
-24.20 MUSD+313.17%
-5.86 MUSD+15.57%
-5.07 MUSD—
Access this data via the Eulerpool API

Celcuity Stock analysis

What does Celcuity do? Celcuity Inc is a biotechnology company founded by Brian Sullivan in 2012. The company is headquartered in Minneapolis, USA. The business model of Celcuity is based on researching and developing new diagnostic and treatment methods for various types of cancer. The company utilizes a proprietary technology platform called CELx, which enables the analysis of cancer cell signaling pathways and the development of individualized treatment strategies. Celcuity specializes in the development of diagnostics and personalized therapies based on individual cancer cell signaling pathways. The company operates in two divisions: 1. Diagnostics division: Celcuity's diagnostics division focuses on identifying new cancer markers and biomarkers for early detection of cancer and the development of individualized treatment strategies. 2. Therapy division: Celcuity's therapy division specializes in the development of personalized therapies based on individual cancer cell signaling pathways. Celcuity currently offers two products based on the CELx technology platform: 1. CELx HUB: CELx HUB is a cloud-based software that allows doctors and researchers to analyze cancer samples and develop individualized treatment strategies. 2. CELx TIL: CELx TIL is a diagnostic tool that measures the presence of tumor cells in the immune system of cancer patients. In summary, Celcuity Inc is a leader in the field of personalized cancer therapy based on individual cancer cell signaling pathways. The company has found a niche in this growing market and has a unique technology platform that allows it to serve its customers effectively. With its products and services, Celcuity is helping to revolutionize cancer treatment and improve the quality of life for cancer patients worldwide. Celcuity is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Celcuity stock

Net Debt of Celcuity is -119.59 M USD in 2025.

Net Debt of Celcuity changed from -137.38 M USD to -119.59 M USD, representing a -12.95% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt Celcuity since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Celcuity historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Celcuity

All Key Metrics — Celcuity